Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial-Reference-Cited by-同舟云学术

Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial

Published:2022-02 Issue:2 Volume:164 Page:254-264
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Harter Philipp,Mouret-Reynier Marie Ange,Pignata Sandro,Cropet Claire,González-Martín Antonio,Bogner Gerhard,Fujiwara Keiichi,Vergote Ignace,Colombo Nicoletta,Nøttrup Trine Jakobi,Floquet Anne,El-Balat Ahmed,Scambia Giovanni,Guerra Alia Eva Maria,Fabbro Michel,Schmalfeldt Barbara,Hardy-Bessard Anne-Claire,Runnebaum Ingo,Pujade-Lauraine Eric,Ray-Coquard Isabelle

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference30 articles.

1. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Ledermann;Ann. Oncol.,2013

2. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials

3. Incorporation of bevacizumab in the primary treatment of ovarian cancer;Burger;N. Engl. J. Med.,2011

4. A phase 3 trial of bevacizumab in ovarian cancer;Perren;N. Engl. J. Med.,2011

5. Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer;Tewari;J. Clin. Oncol.,2019

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of molecular testing on the surgical management of advanced epithelial ovarian cancer;Critical Reviews in Oncology/Hematology;2024-10

2. Prognostic analysis of peritoneal washing cytology during interval debulking surgery in advanced ovarian cancer;Journal of Ovarian Research;2024-08-24

3. Secondary Cytoreductive Surgery in Relapsed Platinum-Sensitive Epithelial Ovarian Cancer: A Systematic Review of Randomized Controlled Trials;Cancers;2024-07-22

4. A single institutional clinical outcome for stages III and IV ovarian cancer patients treated with dose‐dense TC therapy in the frontline or first platinum‐sensitive relapse setting;Journal of Obstetrics and Gynaecology Research;2024-07-02

5. Real-world Study on the Effect of PARPi as Maintenance Therapy on Platinum Sensitivity after First- and Second-line Chemotherapy in Patients with Recurrent High-grade Serous Epithelial Ovarian Cancer;Current Cancer Drug Targets;2024-07